Literature DB >> 2063080

[Pallido-pyramidal syndrome: an unrecognized entity].

C Tranchant1, C Boulay, J M Warter.   

Abstract

A female teenager, without familial history, presented, since the age of 13 years, with gradually worsening pyramidal signs and a parkinsonian syndrome controlled by L-Dopa in small doses. The clinical complex was suggestive of the pallido-pyramidal syndrome, an entity which was individualized in 1954 by Davison on the basis of 5 young patients who had pyramidal signs and a parkinsonian syndrome. In only one of these patients a pathological study was carried out, disclosing a non specific degeneration without inclusions, involving the pallidum, substantia nigra and pyramidal tract. We hope that this report will encourage other authors to report similar cases, since only the study of new cases will determine whether the pallido-pyramidal syndrome is a true entity.

Entities:  

Mesh:

Year:  1991        PMID: 2063080

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  4 in total

1.  Pallido-pyramidal syndrome with blepharospasm and good response to levodopa.

Authors:  Trilochan Srivastava; Vinay Goyal; Sumit Singh; Garima Shukla; Madhuri Behari
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

2.  Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays.

Authors:  Seyedmehdi Shojaee; Farzad Sina; Setareh Sadat Banihosseini; Mohammad Hossein Kazemi; Reza Kalhor; Gholam-Ali Shahidi; Hossein Fakhrai-Rad; Mostafa Ronaghi; Elahe Elahi
Journal:  Am J Hum Genet       Date:  2008-06       Impact factor: 11.025

3.  Characterization of the porcine FBX07 gene: the first step towards generation of a pig model for Parkinsonian pyramidal syndrome.

Authors:  Knud Larsen; Christian Bendixen
Journal:  Mol Biol Rep       Date:  2011-05-25       Impact factor: 2.316

4.  Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations.

Authors:  Coro Paisán-Ruiz; Rocio Guevara; Monica Federoff; Hasmet Hanagasi; Fardaz Sina; Elahe Elahi; Susanne A Schneider; Petra Schwingenschuh; Nin Bajaj; Murat Emre; Andrew B Singleton; John Hardy; Kailash P Bhatia; Sebastian Brandner; Andrew J Lees; Henry Houlden
Journal:  Mov Disord       Date:  2010-09-15       Impact factor: 10.338

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.